<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802645</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-CELIM2-050</org_study_id>
    <secondary_id>2011-003288-31</secondary_id>
    <nct_id>NCT01802645</nct_id>
  </id_info>
  <brief_title>Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases</brief_title>
  <acronym>CELIM2</acronym>
  <official_title>Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the following schedules for efficacy with regard to
      response rate in neoadjuvant treatment of patients with non-resectable liver metastases:

        -  Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and

        -  Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with liver metastases from colorectal and without known extrahepatic metastases will
      be screened for this study including ras status (b-raf status according to local standard).

      Patients receive chemotherapy according to the allocation and are re-evaluated for
      resectability every 8 weeks for a maximum of 6 months. Resectable patients will be resected
      and receive an adjuvant treatment to complete 12 cycles.

      In certain circumstances, a second resection is allowed within the study.

      Patients will be randomized using a web-based computer system that allows randomization if
      the key basic characteristics are entered.

      Patients with ras wild-type tumours will be randomized to receive:

        -  Cetuximab/FOLFIRI or

        -  Cetuximab/FOLFOXIRI

      Patients with ras mutations will be randomized to receive:

        -  FOLFOXIRI or

        -  FOLFOXIRI/bevacizumab

      Chemotherapy doses are adjusted to the risk of toxicity in all treatment arms.

      Stratification will be performed according to:

        -  Number of metastases (&lt; 5 vs. ≥ 5 metastases)

        -  Primary tumour in situ

        -  Centre

      Treatment regimens For dose reductions and conditions to continue please refer to the full
      protocol.

      All drugs are used within the label and approved doses.

      B-raf mutations are determined according to local standard. If a b-raf mutation is known
      before randomization, the investigator can consider the patient as ras wildtype OR as ras
      mutant patient.

      Cetuximab/FOLFIRI :

      Cetuximab 400 mg/m² (first dose, 2 h), then 250 mg/m² (1 h) weekly Irinotecan 180 mg/m², d-l
      Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks

      Cetuximab/FOLFOXIRI:

      Cetuximab 400 mg/m² (first dose, 2 h), then 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² ,
      Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2
      weeks

      FOLFOXIRI:

      Irinotecan 165 mg/m², Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200
      mg/m² (46 h) every 2 weeks

      Bevacizumab/FOLFOXIRI:

      Bevacizumab 5 mg/kg (90 - 30 min i.v.), Irinotecan 165 mg/m², Oxaliplatin 85 mg/m² (2 h), d-l
      Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks

      Evaluation for response and resections Patients are evaluated for response by the same
      imaging technique as at baseline every 8 weeks. The findings will be discussed for
      resectability within two weeks after tumour assessment in a local multidisciplinary team.

      Technically resectable patients should be offered liver resection. The treatment will
      continue until liver resection or for a maximum of six months (12 cycles).

      Adjuvant treatment After liver resection, an adjuvant treatment is recommended with the same
      schedule as preoperatively, for a maximum combined pre- and postoperative treatment of 12
      cycles. If less than three postoperative cycles remain, no postoperative treatment will be
      started (see chapter 9.10).

      Follow up After resection, patients will be followed up for 5 years after randomization. This
      includes

        -  imaging and clinical investigation every three months for the first 2 years, then every
           six months (patients without tumour progression / recurrence)

        -  survival status and surgical/medical treatment every three months for the first 2 years
           and then every six months (all patients)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Rate of patients with partial or complete response according to modified RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of resected patients without early relaps</measure>
    <time_frame>6 months after resection</time_frame>
    <description>Rate of patients who had a R0 resection of all lesions and are disease free for at least 6 months in the ITT population.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Resection rate, defined as patients with microscopically complete (R0) resection (ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Resection rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Rate of liver resection with macroscopically tumour free margins and/or RFA (all patients with R0 or R1 resection and/or complete RFA of all lesion, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 3 years after randomization</time_frame>
    <description>Progression free survival (Medium, Kaplan-Meier-estimation, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival after resection</measure>
    <time_frame>up to 3 years after resection</time_frame>
    <description>Disease free survival after resection (Medium, Kaplan-Meier-estimation, resected patients)</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 year after randomization</time_frame>
    <description>Overall survival (Kaplan-Meier-estimation, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Toxicity according to NCI-CTC criteria v. 4.0 Perioperative toxicity according to Clavien</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathological response</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Pathological response in the resected tumour tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular markers</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>Evaluation of molecular predictive markers for response (i.e. other mutations in EGFR signalling pathway, EGFR ligands) and toxicity</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Leukovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients can be enrolled, if all of these conditions apply:

          1. Non-resectable, histologically confirmed, synchronous or metachronous colorectal liver
             metastases.

          2. Non-resectability will be documented by a local multidisciplinary tumour board with
             participation of a surgeon experienced in liver surgery. Patients can be enrolled if
             they

             a) are technically non-resectable (locally determined by a multi-disciplinary team
             discussion based on remaining functional liver tissue after resection, i.e. i)
             involvement of both portal veins, all hepatic veins, portal vein of the liver lobe and
             hepatic veins draining the segments of the other liver lobe, or ii) other reasons for
             less than 30% remaining functional liver tissue after resection) and / or b) have ≥ 5
             liver metastases and / or c) are regarded as non-resectable for other reasons
             (description necessary)

          3. Patients with simultaneous liver metastases are eligible,

               1. if the primary tumour was resected at least 1 month prior to chemotherapy or

               2. all of the following conditions apply:

             i) the primary tumour is clearly resectable, ii) no radiation therapy is planned, iii)
             liver resection is planned before resection of the primary or at the same operation as
             the resection of the primary, iv) no two-stage liver resection is planned, and v) all
             efforts were made to exclude additional distant metastases.

          4. WHO PS ≤ 1

          5. Written informed consent

          6. Adequate bone marrow function, liver function (neutrophils &gt; 1.5 x 109/l; platelets &gt;
             100 x 109/l; haemoglobin &gt; 5.0 mmol/l (8.0 g/dl); bilirubin ≤ ULN or ≤ 1.5 x ULN and
             not increasing more than 25 % within the last 4 weeks; SGOT and SGPT &lt; 5 x UNL)

          7. Age ≥ 18 years

        Exclusion Criteria:

          1. Any evidence of extrahepatic metastases, distant lymph node metastases and primary
             tumour recurrence

          2. (deleted)

          3. Prior systemic anti-tumour therapy with anti- EGFR-, anti-angiogenetic drugs or with
             chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months or in
             combination with radiation as radio sensitizer)

          4. Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic
             interventions or venous port implantation) ≤ 4 weeks before study entry

          5. Renal insufficiency with serum creatinine ≥ 1.5 x UNL. If serum creatinine is between
             1.0 and 1.5 x UNL, the creatinine clearance according to the Cockroft-Gault formula
             should be ≥ 60 ml/min

          6. Hypertension with an arterial blood pressure &gt; 150/90 mmHg

          7. Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV, unstable angina pectoris, history of myocardial infarction within the last 12
             months, significant arrhythmias)

          8. Known proteinuria &gt; 1 g/day (to be tested if proteinuria more than 1+ in the urinary
             dipstick analysis)

          9. Peripheral neuropathy &gt; CTC grade I

         10. Concurrent systemic immune therapy, chemotherapy, hormone therapy, or patients
             receiving immune suppressive treatment (i.e. for transplantation, severe rheumatologic
             disease)

         11. Participation in clinical trials with investigational agents within 30 days before
             start of the treatment in study

         12. Active treatment of

               1. peptic ulcers or bleeding erosive esophagitis / gastritis within 3 months before
                  study

               2. pulmonary embolism, severe or unstable angina pectoris or myocardial infarction,
                  stroke or transient ischemic attack within 12 months before study

               3. deep vein thrombosis within 4 weeks before study

         13. Inflammatory bowel disease

         14. History of other malignancies, from which the patient is not 5 years disease free,
             with the exception of colorectal cancer, or adequately treated basal cell or squamous
             cell carcinoma of skin or in-situ cervical cancer within 5 years before study

         15. History of brain metastases

         16. History of severe psychiatric illness

         17. Active drug- or alcohol abuse

         18. Known hepatitis B or C or HIV infection

         19. Breast- feeding or pregnant women

         20. Lack of effective contraception (for male and female patients)

         21. Known intolerance to one of the following drugs: cetuximab, bevacizumab, oxaliplatin,
             irinotecan, 5-FU, folinic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Folprecht, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital &quot;Carl Gustav Carus&quot; Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunnar Folprecht, PD Dr.</last_name>
    <phone>+49 351 458 4794</phone>
    <email>Gunnar.Folprecht@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Schubert</last_name>
    <phone>+49 351 79 656 20</phone>
    <email>Olga.Schubert@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf-Peter Neumann, Prof. Dr.</last_name>
      <phone>0241 8085660</phone>
      <email>chirurgie@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Ulf-Peter Neumann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Seehofer, PD Dr. med.</last_name>
      <phone>030/ 450 652062</phone>
      <email>daniel.seehofer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Seehofer, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis Hämatologie/ Onkologie</name>
      <address>
        <city>Bocholt</city>
        <zip>46397</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volker Burstedde, Dr. med.</last_name>
      <phone>02871/2182669</phone>
      <email>Dr.burstedde@gmx.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christof Lamberti, PD Dr. med.</last_name>
      <phone>09561 / 22-5413</phone>
      <email>christof.lamberti@klinikum-coburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologie Dülmen GbR</name>
      <address>
        <city>Coesfeld</city>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manfred Glados, Dr. med.</last_name>
      <phone>02541/971893</phone>
      <email>onko-studien@glados.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Folprecht, PD Dr. med.</last_name>
      <phone>+49 351 458 4794</phone>
      <email>Gunnar.Folprecht@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Olga Schubert</last_name>
      <phone>+49 351 7965620</phone>
      <email>olga.schubert@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gunnar Folprecht, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt/ Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolf Otto Bechstein, Prof. Dr.</last_name>
      <email>wolf.bechstein@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Liersch, PD Dr. med.</last_name>
      <phone>0551/ 398323</phone>
      <email>tliersch@chirurgie-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Torsten Liersch, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Arnold, Prof. Dr.</last_name>
      <phone>040/ 7410 55489</phone>
      <email>d.arnold@uke.de</email>
    </contact>
    <investigator>
      <last_name>Dirk Arnold, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut gGmbH</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Loehe, Prof. Dr.</last_name>
      <phone>0871 698 3338</phone>
      <email>florian.loehe@klinikum-landshut.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Lordick, Pr.</last_name>
      <phone>+49 341 97 12560</phone>
      <email>Florian.Lordick@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Florian Lordick, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Möhler, PD Dr.</last_name>
      <phone>+49 6131 17 6863</phone>
      <email>markus.moehler@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Markus Möhler, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus-Henning Köhne, Prof. Dr.</last_name>
      <phone>+49 441 403-2610</phone>
      <email>onkologie@klinikum-oldenburg.de</email>
    </contact>
    <investigator>
      <last_name>Claus-Henning Köhne, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum Winnenden</name>
      <address>
        <city>Winnenden</city>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Schaich, Prof. Dr.</last_name>
      <phone>07195-591 39240</phone>
      <email>Markus.Schaich@rems-murr-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Kunzmann, PD Dr. med.</last_name>
      <phone>0931/20140746</phone>
      <email>kunzmann_v@medizin.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Volker Kunzmann, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant</keyword>
  <keyword>cetuximab</keyword>
  <keyword>irinotecan</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>5-FU</keyword>
  <keyword>Resection</keyword>
  <keyword>colorectal liver metastases</keyword>
  <keyword>liver resection</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>k-ras</keyword>
  <keyword>non-resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

